SCHEMBL4084978

SCHEMBL4084978

CCOC(=O)N1CCN(c2nc(-c3ccccc3F)nc3ccc(Cl)cc23)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
MEN1 O00255 8/20 0.54
KMT2A Q03164 8/20 0.54
LMNA P02545 4/20 0.49
HSD17B10 Q99714 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 3/20 0.49
CASP1 P29466 2/20 0.49
CASP7 P55210 1/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
GLA P06280 1/20 0.49
IDE P14735 1/20 0.48
KCNH2 Q12809 1/20 0.48
HIF1A Q16665 1/20 0.47
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1084821 0.91 MAPT (0.54) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL4091440 0.91 KMT2A (0.55) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL1084085 0.88 MEN1 (0.67) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL4097266 0.88 MAPT (0.59) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL4095191 0.88 MAPT (0.62) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL4093148 0.85 KMT2A (0.54) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL1084320 0.85 MEN1 (0.55) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL4097528 0.84 MEN1 (0.54) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL1084845 0.84 MAPT (0.54) MAPTMEN1KMT2ALMNAHSD17B10
SCHEMBL4090724 0.83 KMT2A (0.55) MAPTMEN1KMT2ALMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MAPT 4125/4885MEN1 718/4885KMT2A 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.